Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality
worldwide; many recent advances have been made in many aspects of the disease. The aim …

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder and patients
respond differently to treatment. Blood eosinophils are a potential biomarker to stratify …

Precision medicine is a patient-specific approach that integrates all relevant clinical, genetic
and biological information in order to optimise the therapeutic benefit relative to the …

Background: Chronic obstructive pulmonary disease (COPD) is characterized by persistent
respiratory symptoms and dyspnea, as well as an increase in the number of leukocytes in …

Pharmacological treatment for chronic obstructive pulmonary disease (COPD) aims to
alleviate symptoms and reduce the future risk of events such as exacerbations, disease …

Inhaled corticosteroids (ICS) are widely used to treat patients with chronic obstructive
pulmonary disease (COPD). Their main impact is to reduce the risk of exacerbations; in …

Identification of a biomarker that predicts response to inhaled corticosteroids (ICS) would
help evaluate the risk/benefit profile of ICS in chronic obstructive pulmonary disease (COPD) …

In an era of precision medicine, it seems regressive that we do not use stratified approaches
to direct treatment of oral corticosteroids during an exacerbation of chronic obstructive …

Background Chronic obstructive pulmonary disease (COPD) is characterised by progressive
airflow limitation and chronic inflammation. Predicting exacerbations of COPD, which …

Introduction There is an interest in the role of blood eosinophils for predicting inhaled
corticosteroid (ICS) response in chronic obstructive pulmonary disease (COPD). Most data …